Journal
ONCOTARGET
Volume 6, Issue 29, Pages 27440-27460Publisher
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.4578
Keywords
prostate cancer; androgen receptors (AR/AR-V7); galeterone (gal); gal's analog VNPT55; mechanisms of AR/AR-V7 degradation
Categories
Funding
- NIH
- NCI [RO1CA129379]
- University of Maryland School of Medicine, Center for Biomolecular Therapeutics (CBT)
- Marlene Stewart Greenebaum Cancer Center (Philanthropic Funds), Baltimore, USA
- University of Maryland School of Medicine Toxicology Program
Ask authors/readers for more resources
Galeterone (Gal) is a first-in-class multi-target oral small molecule that will soon enter pivotal phase III clinical trials in castration resistant prostate cancer (CRPC) patients. Gal disrupts androgen receptor (AR) signaling via inhibition of CYP17, AR antagonism and AR degradation. Resistance to current therapy is attributed to up-regulation of full-length AR (fAR), splice variants AR (AR-Vs) and AR mutations. The effects of gal and VNPT55 were analyzed on f-AR and AR-Vs (AR-V7/AR(v567es)) in LNCaP, CWR22Rv1 and DU145 (transfected with AR-Vs) human PC cells in vitro and CRPC tumor xenografts. Galeterone/VNPT55 decreased fAR/AR-V7 mRNA levels and implicates Mdm2/CHIP enhanced ubiquitination of posttranslational modified receptors, targeting them for proteasomal degradation. Gal and VNPT55 also induced significant apoptosis in PC cells via increased Bax/Bcl2 ratio, cytochrome-c release with concomitant cleavage of caspase 3 and PARP. More importantly, gal and VNPT55 exhibited strong in vivo anti-CRPC activities, with no apparent host toxicities. This study demonstrate that gal and VNPT55 utilize cell-based mechanisms to deplete both fAR and AR-Vs. Importantly, the preclinical activity profiles, including profound apoptotic induction and inhibition of CRPC xenografts suggest that these agents offer considerable promise as new therapeutics for patients with CRPC and those resistant to current therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available